Mycoplasma pneumoniae is a trigger for autoimmune pathology.

An evidence-based assessment of the relationship between Mycoplasma pneumoniae infection and autoimmune phenomena is detailed below.

Mechanistic pathways of autoimmunity

Mycoplasma pneumoniae triggers autoimmune phenomena through two complementary pathways that dysregulate host self-tolerance:

• Molecular mimicry and cross-reactive antibodies: Structural homologies between mycoplasmal membrane glycolipids and host cell-surface antigens drive the production of cross-reactive antibodies.
  • Neurological manifestations: Antibodies generated against mycoplasmal glycolipids cross-react with host neural myelin glycolipids, particularly galactocerebroside (GalC) and gangliosides (such as GM1b). These cross-reactive anti-GalC and anti-ganglioside antibodies target peripheral nerves, directly driving acute inflammatory demyelinating neuropathies, including Guillain-Barré syndrome (GBS).
  • Hematologic manifestations: The infection routinely induces the production of cold agglutinins—specifically IgM antibodies directed against the "I" antigen on human erythrocyte membranes. Under cool temperatures, these autoantibodies bind red blood cells and activate the complement cascade, causing intravascular or extravascular hemolytic anemia.
• Polyclonal B-cell activation and cytokine cascades: M. pneumoniae membranes act as potent B-cell mitogens, triggering non-specific, polyclonal B-cell activation. This produces a wide range of low-affinity autoantibodies. Concurrently, infection activates Toll-like receptors (TLR2 and TLR4), initiating robust inflammatory cytokine cascades. This include Th17-mediated pathways (characterized by elevated IL-17A, IL-6, and TNF-alpha), which sustain systemic inflammation and lower the threshold for broad autoimmune manifestations.

Clinical evidence and manifestations

Clinical studies and observational cohorts document a clear link between M. pneumoniae infection and diverse autoimmune extrapulmonary manifestations:

• Post-infectious neurological syndromes: Beyond GBS, clinical evidence links M. pneumoniae to acute disseminated encephalomyelitis (ADEM), transverse myelitis, and encephalitis. Patients with neurological complications frequently show elevated titers of anti-GalC IgG/IgM in both serum and cerebrospinal fluid.
• Mucocutaneous and systemic manifestations: Polyclonal immune activation and antigen-antibody complex deposition are primary drivers of M. pneumoniae-induced rash and mucositis (MIRM), Stevens-Johnson syndrome (SJS), and reactive arthritis. The systemic deposition of these immune complexes can also lead to membranous glomerulonephritis and vasculitis.

Bottom line

Mycoplasma pneumoniae is a well-established trigger for autoimmune pathology. It drives autoantibody-mediated damage through precise molecular mimicry (such as anti-GalC antibodies in GBS and cold agglutinins in hemolytic anemia) alongside non-specific, polyclonal B-cell activation and systemic Th17-skewed inflammation.